Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein–Barr virus lytic reactivation
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0299198 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kelly L Gorres und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, Connecticut, United States of America. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, University of Wisconsin-La Crosse.
Abstract (Originalsprache)
Herpesviruses have two distinct life cycle stages, latency and lytic replication. Epstein-Barr virus (EBV), a gamma-herpesvirus, establishes latency in vivo and in cultured cells. Cell lines harboring latent EBV can be induced into the lytic cycle by treatment with chemical inducing agents. In the Burkitt lymphoma cell line HH514-16 the viral lytic cycle is triggered by butyrate, a histone deacetylase (HDAC) inhibitor. Butyrate also alters expression of thousands of cellular genes. However, valproic acid (VPA), another HDAC inhibitor with global effects on cellular gene expression blocks EBV lytic gene expression in Burkitt lymphoma cell lines. Valpromide (VPM), an amide derivative of VPA, is not an HDAC inhibitor, but like VPA blocks induction of the EBV lytic cycle. VPA and VPM are the first examples of inhibitors of initial stages of lytic reactivation. We compared the effects of VPA and VPM, alone and in combination with butyrate, on host cellular gene expression using whole transcriptome analysis (RNA-seq). Gene expression was analyzed 6 h after addition of the compounds, a time before the first EBV lytic transcripts are detected. The results address two alternative, yet possibly complementary, mechanisms for regulation of EBV lytic reactivation. First, cellular genes that were up- or down-regulated by butyrate, but no longer altered in the presence of VPA or VPM, represent genes that correlated with EBV lytic reactivation. Second, genes regulated similarly by VPA and VPM in the absence and presence of butyrate are candidates for suppressors of EBV reactivation. Two genes upregulated by the lytic cycle inhibitors, CHAC1 and SLC7A11 , are related to redox status and the iron-dependent cell death pathway ferroptosis. This study generates new hypotheses for control of the latency to lytic cycle switch of EBV and provides the first description of effects of the anti-convulsant drug VPM on global human cellular gene expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, Connecticut, United States of America.
- Department of Mathematics and Statistics and Statistics Consulting Center, University of Wisconsin-La Crosse, La Crosse, Wisconsin, United States of America.
- Department of Pediatrics and Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, Connecticut, United States of America.
ORCID-Profile: Kelly L Gorres, George Miller
Förderung
- NCI NIH HHS
- National Cancer Institute
- University of Wisconsin-La Crosse
Zitieren
APA
Gorres, K. L., Reineke, D. M., & Miller, G. (2024). Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein–Barr virus lytic reactivation. PLOS ONE. https://doi.org/10.1371/journal.pone.0299198
Vancouver
Gorres KL, Reineke DM, Miller G. Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein–Barr virus lytic reactivation. PLOS ONE. 2024. doi:10.1371/journal.pone.0299198
BibTeX
@article{Gorres2024,
author = {Gorres, Kelly L and Reineke, David M and Miller, George},
title = {Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein–Barr virus lytic reactivation},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0299198}
}
EUVIMED